Recently, it has been reported that inhibition of Hsp90 suppresses lipid synthesis via directly promoting the degradation of sterol regulatory element-binding protein 1 (SREBP1) and SREBP2.77–79 Here, our study proposes an independent mechanism by which the Hsp90 inhibitors function in the treatment of NAFLD and obesity. This evidence concerns the gene SREBF2 and obesity disorder.